Lovingly Park

Lovingly Park's work experience includes a position as Director of Clinical Development at Alector, where they provided strategic direction, led staff, and collaborated on clinical development programs. They also held a role as a Neuroscience Steering Committee Member at the Foundation for the National Institutes of Health. Prior to that, they served as Director of Clinical Research at Supernus Pharmaceuticals, Inc., leading the design and execution of clinical studies in Epilepsy. They also gained experience at Parexel as a Director of Scientific Affairs and Investigator, conducting scientific research and managing affairs. They have a background as a Postdoctoral Scholar and Postdoctoral Fellow at UC Davis Medical Center, where they specialized in neuroanatomy and cognitive functionality. Additionally, they have interned at UC San Diego Health, conducted research at UCSF Medical Center, and worked as a Project Coordinator at UC Irvine Health.

Lovingly Park's education history began in 2000 when they obtained a B.A. in Psychology and Social Behavior from UC Irvine. In 2003, Lovingly Park pursued a Ph.D. in Clinical Psychology at Alliant International University-San Francisco Bay, which was completed in 2009. During this time, from 2003 to 2007, they also engaged in a Practicum in Neuropsychology at the University of California, San Francisco. In 2007, Lovingly Park undertook a Predoctoral Internship in Neuropsychology at UC San Diego, which lasted until 2008. Following this, they continued their education at the University of California, Davis - School of Medicine, where they served as a Postdoctoral Scholar from 2008 to 2010. Ultimately, in 2010, Lovingly Park engaged in a Post-Doctoral Fellowship in Neuroimaging at the University of California, Davis - School of Medicine, which concluded in 2013. Finally, in 2022, Lovingly Park pursued further education at the University of California, San Francisco, where they completed the UCSF-Stanford CERSI Immersion Course in Drug Discovery, Drug Development, and Regulation.